Altered serum glycomics in Alzheimer disease: A potential blood biomarker?

Rejuvenation Research

Volumn 13, Issue 4, 2010, Pages 439-444

  Chen, Cuiying Chitty ^a,b   Engelborghs, Sebastiaan ^c,d,f,g   Dewaele, Sylviane ^a,b   Le Bastard, Nathalie ^d   Martin, Jean Jacques ^e   Vanhooren, Valerie ^a,b   Libert, Claude ^a,b   De Deyn, Peter Paul ^c,d,e,g  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g Hogeschool Antwerpen   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GLYCAN; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELECTROPHORESIS; FEMALE; GLYCOBIOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

ADULT; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CARBOHYDRATES; CASE-CONTROL STUDIES; ELECTROPHORESIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOMICS; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 77956119701     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0992     Document Type: Article

References (35)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
2. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2008;31:357-367.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
4. Dubois B, Feldman HH, Jacova C, DeKosky S, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
5. Knopman D. Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease. Arch Neurol 2001;58:349-350.
6. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clinical neurology and neurosurgery 2005;107(3):165-173
7. Engelborghs S, De Vreese K, Van de Casteele T, Vandersti-chele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29:1143-1159.
8. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 2009;(in press).
9. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 2009;55:214-218.
10. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2006;21:9-15.
11. Kukuruzinska MA, Lennon K. Protein N-glycosylation: Molecular genetics and functional significance. Crit Rev Oral Biol Med 1998;9:415-448.
12. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasi-sekharan R. Glycomics: An integrated systems approach to structure-function relationships of glycans. Nat Methods 2005;2:817-824.
13. Vanhooren V, Desmyter L, Liu XE, Cardelli M, Franceschi C, Federico A, Libert C, Laroy W, Dewaele S, Contreras R, Chen C. N-glycomic changes in serum proteins during human aging. Rejuvenation Res 2007;10:521-531a.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-198.
15. Engelborghs S, De Vreese K, Van de Casteele T, Vandersti-chele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29:1143-1159.
16. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropatholog 1991;82:239-259.
17. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofi-brillary pathology using paraffin sections and immunocy-tochemistry. Acta Neuropatholog 2006;112:389-404.
18. Jellinger KA. The neuropathological diagnosis of Alzheimer disease. J Neural Transmission 1998;53:97-118.
19. Jackson M, Lowe J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropatholog 1996;91: 127-134.
20. Markesbery WR (ed). Neuropathology of dementing disorders. Arnold: London, UK, 1998.
21. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol 1988;7:299-305.
22. Vanhooren V, Laroy W, Libert C, Chen C. N-Glycan profiling in the study of human aging. Biogerontology 2008;9:351-356.
23. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314:777-781.
24. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schrö der J, Zinkowski RP, Bouwman FH, Schönknecht P, Schoon-enboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69:2205-2212.
25. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 2004;23:115-122.
26. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989;57:115-126.
27. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Gong CX. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phos-phatase 2A and 5. Neuroscience 2002;115:829-837.
28. Sato Y, Naito Y, Grundke-Iqbal I, Iqbal K, Endo T. Analysis of N-glycans of pathological tau: possible occurrence of aberrant processing of tau in Alzheimer's disease. FEBS Lett 2001;496:152-160.
29. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule- associated protein tau: an abnormal posttrans-lational modification in Alzheimer's disease. Nat Med 1996; 2:871-875.
30. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, Gong CX. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett 2002;512:101-106.
31. Suzuki T, Araki Y, Yamamoto T, Nakaya T. Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J Biochem 2006;139: 949-955.
32. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008;5:212-224.
33. Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Knölker HJ, Simons K. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 2008;320:520-523.
34. Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Targeted proteomics in Alzheimer's disease: Focus on amyloid-beta. Expert Rev Proteomics 2008;5:225-237.
35. Orlacchio A, Bernardi G, Orlacchio A, Martino S. RNA interference as a tool for Alzheimer's disease therapy. Mini Rev Medic Chem 2007;7:1166-1176.